株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

がん免疫療法の世界市場の分析

Global Cancer Immunotherapy Market (2018 - 2024)

発行 KBV Research 商品コード 763723
出版日 ページ情報 英文 229 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.74円で換算しております。
Back to Top
がん免疫療法の世界市場の分析 Global Cancer Immunotherapy Market (2018 - 2024)
出版日: 2018年12月20日 ページ情報: 英文 229 Pages
概要

当レポートでは、世界のがん免疫療法市場について調査分析し、市場概要、セグメント別の市場分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

第1章 市場範囲・手法

第2章 市場概要

  • イントロダクション
  • 市場影響要因

第3章 世界のがん免疫療法市場:技術別

  • モノクローナル抗体
  • サイトカイン・免疫刺激剤
  • その他

第4章 世界のがん免疫療法市場:適応別

  • 肺がん
  • 乳がん
  • 大腸がん
  • 黒色腫 (メラノーマ)
  • 前立腺がん
  • 頭頸部がん
  • その他

第5章 世界のがん免疫療法市場:エンドユーザー別

  • 病院
  • クリニック
  • その他

第6章 世界のがん免疫療法市場:地域別

  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ・中東・アフリカ

第7章 企業プロファイル

  • Amgen Inc.
  • Merck & Company, Inc.
  • Pfizer Inc.
  • Immunomedics Inc.
  • Astrazeneca Plc.
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly and Company
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Bayer AG
図表

LIST OF TABLES

  • TABLE 1: GLOBAL CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 2: GLOBAL CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 3: GLOBAL CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 4: GLOBAL CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 5: GLOBAL MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY REGION, 2014 - 2017, USD MILLION
  • TABLE 6: GLOBAL MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY REGION, 2018 - 2024, USD MILLION
  • TABLE 7: GLOBAL CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY REGION, 2014 - 2017, USD MILLION
  • TABLE 8: GLOBAL CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY REGION, 2018 - 2024, USD MILLION
  • TABLE 9: GLOBAL OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY REGION, 2014 - 2017, USD MILLION
  • TABLE 10: GLOBAL OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY REGION, 2018 - 2024, USD MILLION
  • TABLE 11: GLOBAL CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 12: GLOBAL CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 13: GLOBAL CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY REGION, 2014 - 2017, USD MILLION
  • TABLE 14: GLOBAL CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY REGION, 2018 - 2024, USD MILLION
  • TABLE 15: GLOBAL CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY REGION, 2014 - 2017, USD MILLION
  • TABLE 16: GLOBAL CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY REGION, 2018 - 2024, USD MILLION
  • TABLE 17: GLOBAL CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY REGION, 2014 - 2017, USD MILLION
  • TABLE 18: GLOBAL CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY REGION, 2018 - 2024, USD MILLION
  • TABLE 19: GLOBAL CANCER IMMUNOTHERAPY MELANOMA MARKET BY REGION, 2014 - 2017, USD MILLION
  • TABLE 20: GLOBAL CANCER IMMUNOTHERAPY MELANOMA MARKET BY REGION, 2018 - 2024, USD MILLION
  • TABLE 21: GLOBAL CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY REGION, 2014 - 2017, USD MILLION
  • TABLE 22: GLOBAL CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY REGION, 2018 - 2024, USD MILLION
  • TABLE 23: GLOBAL CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY REGION, 2014 - 2017, USD MILLION
  • TABLE 24: GLOBAL CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY REGION, 2018 - 2024, USD MILLION
  • TABLE 25: GLOBAL OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY REGION, 2014 - 2017, USD MILLION
  • TABLE 26: GLOBAL OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY REGION, 2018 - 2024, USD MILLION
  • TABLE 27: GLOBAL CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 28: GLOBAL CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 29: GLOBAL HOSPITALS CANCER IMMUNOTHERAPY MARKET BY REGION, 2014 - 2017, USD MILLION
  • TABLE 30: GLOBAL HOSPITALS CANCER IMMUNOTHERAPY MARKET BY REGION, 2018 - 2024, USD MILLION
  • TABLE 31: GLOBAL CLINICS CANCER IMMUNOTHERAPY MARKET BY REGION, 2014 - 2017, USD MILLION
  • TABLE 32: GLOBAL CLINICS CANCER IMMUNOTHERAPY MARKET BY REGION, 2018 - 2024, USD MILLION
  • TABLE 33: GLOBAL OTHER END USER CANCER IMMUNOTHERAPY MARKET BY REGION, 2014 - 2017, USD MILLION
  • TABLE 34: GLOBAL OTHER END USER CANCER IMMUNOTHERAPY MARKET BY REGION, 2018 - 2024, USD MILLION
  • TABLE 35: GLOBAL CANCER IMMUNOTHERAPY MARKET BY REGION, 2014 - 2017, USD MILLION
  • TABLE 36: GLOBAL CANCER IMMUNOTHERAPY MARKET BY REGION, 2018 - 2024, USD MILLION
  • TABLE 37: NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 38: NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 39: NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 40: NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 41: NORTH AMERICA MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 42: NORTH AMERICA MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 43: NORTH AMERICA CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 44: NORTH AMERICA CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 45: NORTH AMERICA OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 46: NORTH AMERICA OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 47: NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 48: NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 49: NORTH AMERICA CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 50: NORTH AMERICA CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 51: NORTH AMERICA CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 52: NORTH AMERICA CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 53: NORTH AMERICA CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 54: NORTH AMERICA CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 55: NORTH AMERICA CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 56: NORTH AMERICA CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 57: NORTH AMERICA CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 58: NORTH AMERICA CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 59: NORTH AMERICA CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 60: NORTH AMERICA CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 61: NORTH AMERICA OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 62: NORTH AMERICA OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 63: NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 64: NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 65: NORTH AMERICA HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 66: NORTH AMERICA HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 67: NORTH AMERICA CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 68: NORTH AMERICA CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 69: NORTH AMERICA OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 70: NORTH AMERICA OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 71: NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 72: NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 73: US CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 74: US CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 75: US CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 76: US CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 77: US CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 78: US CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 79: US CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 80: US CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 81: CANADA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 82: CANADA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 83: CANADA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 84: CANADA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 85: CANADA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 86: CANADA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 87: CANADA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 88: CANADA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 89: MEXICO CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 90: MEXICO CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 91: MEXICO CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 92: MEXICO CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 93: MEXICO CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 94: MEXICO CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 95: MEXICO CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 96: MEXICO CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 97: REST OF NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 98: REST OF NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 99: REST OF NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 100: REST OF NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 101: REST OF NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 102: REST OF NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 103: REST OF NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 104: REST OF NORTH AMERICA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 105: EUROPE CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 106: EUROPE CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 107: EUROPE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 108: EUROPE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 109: EUROPE MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 110: EUROPE MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 111: EUROPE CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 112: EUROPE CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 113: EUROPE OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 114: EUROPE OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 115: EUROPE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 116: EUROPE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 117: EUROPE CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 118: EUROPE CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 119: EUROPE CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 120: EUROPE CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 121: EUROPE CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 122: EUROPE CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 123: EUROPE CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 124: EUROPE CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 125: EUROPE CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 126: EUROPE CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 127: EUROPE CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 128: EUROPE CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 129: EUROPE OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 130: EUROPE OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 131: EUROPE CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 132: EUROPE CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 133: EUROPE HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 134: EUROPE HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 135: EUROPE CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 136: EUROPE CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 137: EUROPE OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 138: EUROPE OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 139: EUROPE CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 140: EUROPE CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 141: GERMANY CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 142: GERMANY CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 143: GERMANY CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 144: GERMANY CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 145: GERMANY CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 146: GERMANY CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 147: GERMANY CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 148: GERMANY CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 149: UK CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 150: UK CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 151: UK CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 152: UK CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 153: UK CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 154: UK CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 155: UK CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 156: UK CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 157: FRANCE CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 158: FRANCE CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 159: FRANCE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 160: FRANCE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 161: FRANCE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 162: FRANCE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 163: FRANCE CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 164: FRANCE CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 165: RUSSIA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 166: RUSSIA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 167: RUSSIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 168: RUSSIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 169: RUSSIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 170: RUSSIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 171: RUSSIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 172: RUSSIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 173: SPAIN CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 174: SPAIN CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 175: SPAIN CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 176: SPAIN CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 177: SPAIN CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 178: SPAIN CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 179: SPAIN CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 180: SPAIN CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 181: ITALY CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 182: ITALY CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 183: ITALY CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 184: ITALY CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 185: ITALY CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 186: ITALY CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 187: ITALY CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 188: ITALY CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 189: REST OF EUROPE CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 190: REST OF EUROPE CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 191: REST OF EUROPE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 192: REST OF EUROPE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 193: REST OF EUROPE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 194: REST OF EUROPE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 195: REST OF EUROPE CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 196: REST OF EUROPE CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 197: ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 198: ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 199: ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 200: ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 201: ASIA PACIFIC MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 202: ASIA PACIFIC MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 203: ASIA PACIFIC CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 204: ASIA PACIFIC CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 205: ASIA PACIFIC OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 206: ASIA PACIFIC OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 207: ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 208: ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 209: ASIA PACIFIC CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 210: ASIA PACIFIC CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 211: ASIA PACIFIC CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 212: ASIA PACIFIC CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 213: ASIA PACIFIC CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 214: ASIA PACIFIC CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 215: ASIA PACIFIC CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 216: ASIA PACIFIC CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 217: ASIA PACIFIC CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 218: ASIA PACIFIC CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 219: ASIA PACIFIC CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 220: ASIA PACIFIC CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 221: ASIA PACIFIC OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 222: ASIA PACIFIC OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 223: ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 224: ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 225: ASIA PACIFIC HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 226: ASIA PACIFIC HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 227: ASIA PACIFIC CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 228: ASIA PACIFIC CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 229: ASIA PACIFIC OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 230: ASIA PACIFIC OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 231: ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 232: ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 233: CHINA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 234: CHINA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 235: CHINA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 236: CHINA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 237: CHINA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 238: CHINA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 239: CHINA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 240: CHINA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 241: JAPAN CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 242: JAPAN CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 243: JAPAN CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 244: JAPAN CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 245: JAPAN CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 246: JAPAN CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 247: JAPAN CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 248: JAPAN CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 249: INDIA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 250: INDIA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 251: INDIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 252: INDIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 253: INDIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 254: INDIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 255: INDIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 256: INDIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 257: SOUTH KOREA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 258: SOUTH KOREA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 259: SOUTH KOREA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 260: SOUTH KOREA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 261: SOUTH KOREA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 262: SOUTH KOREA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 263: SOUTH KOREA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 264: SOUTH KOREA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 265: SINGAPORE CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 266: SINGAPORE CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 267: SINGAPORE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 268: SINGAPORE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 269: SINGAPORE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 270: SINGAPORE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 271: SINGAPORE CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 272: SINGAPORE CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 273: MALAYSIA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 274: MALAYSIA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 275: MALAYSIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 276: MALAYSIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 277: MALAYSIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 278: MALAYSIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 279: MALAYSIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 280: MALAYSIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 281: REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 282: REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 283: REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 284: REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 285: REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 286: REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 287: REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 288: REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 289: LAMEA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 290: LAMEA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 291: LAMEA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 292: LAMEA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 293: LAMEA MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 294: LAMEA MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 295: LAMEA CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 296: LAMEA CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 297: LAMEA OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 298: LAMEA OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 299: LAMEA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 300: LAMEA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 301: LAMEA CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 302: LAMEA CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 303: LAMEA CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 304: LAMEA CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 305: LAMEA CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 306: LAMEA CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 307: LAMEA CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 308: LAMEA CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 309: LAMEA CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 310: LAMEA CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 311: LAMEA CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 312: LAMEA CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 313: LAMEA OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 314: LAMEA OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 315: LAMEA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 316: LAMEA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 317: LAMEA HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 318: LAMEA HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 319: LAMEA CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 320: LAMEA CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 321: LAMEA OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 322: LAMEA OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 323: LAMEA CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 324: LAMEA CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 325: BRAZIL CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 326: BRAZIL CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 327: BRAZIL CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 328: BRAZIL CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 329: BRAZIL CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 330: BRAZIL CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 331: BRAZIL CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 332: BRAZIL CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 333: ARGENTINA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 334: ARGENTINA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 335: ARGENTINA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 336: ARGENTINA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 337: ARGENTINA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 338: ARGENTINA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 339: ARGENTINA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 340: ARGENTINA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 341: UAE CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 342: UAE CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 343: UAE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 344: UAE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 345: UAE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 346: UAE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 347: UAE CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 348: UAE CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 349: SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 350: SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 351: SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 352: SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 353: SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 354: SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 355: SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 356: SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 357: SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 358: SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 359: SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 360: SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 361: SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 362: SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 363: SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 364: SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 365: NIGERIA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 366: NIGERIA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 367: NIGERIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 368: NIGERIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 369: NIGERIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 370: NIGERIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 371: NIGERIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 372: NIGERIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 373: REST OF LAMEA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 374: REST OF LAMEA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 375: REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 376: REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 377: REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 378: REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 379: REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 380: REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 381: KEY INFORMATION-AMGEN INC.
  • TABLE 382: KEY INFORMATION-MERCK & COMPANY INC.
  • TABLE 383: KEY INFORMATION- PFIZER INC.
  • TABLE 384: KEY INFORMATION- IMMUNOMEDICS INC.
  • TABLE 385: KEY INFORMATION- ASTRAZENECA PLC.
  • TABLE 386: KEY INFORMATION- F. HOFFMANN-LA ROCHE LTD.
  • TABLE 387: KEY INFORMATION - ELI LILLY AND COMPANY
  • TABLE 388: KEY INFORMATION - NOVARTIS AG
  • TABLE 389: KEY INFORMATION - BRISTOL-MYERS SQUIBB COMPANY
  • TABLE 390: KEY INFORMATION - BAYER AG
目次

The Global Cancer Immunotherapy Market size is expected to reach $128.3 billion by 2024, rising at a market growth of 14.3% CAGR during the forecast period.

Cancer immunotherapy is the type of cancer treatment helping the immune system fight cancer. There are various kinds of cancer immunotherapies used and they are monoclonal antibody, therapeutic cancer vaccines, checkpoint inhibitors, cytokines, and others. Growing patient population that is suffering from different types of cancer such as lung cancer, breast cancer, ovarian cancer, and other cancers are the factors that drive the global cancer immunotherapy market. Additionally, growing geriatric population and governmental contribution to healthcare expenditure are some other factors that add to the market growth.

Based on technology, the market is segmented into Monoclonal Antibodies, Cytokines & Immunomodulators and other technology. Based on application, the market is segmented into Lung cancer, Breast cancer, Colorectal, Prostate cancer, Head & Neck cancer and other application. Based on end user the market is segmented into Hospitals, Clinics and other end user.. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca, Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Bayer Ag, Immunomedics Inc., Novartis AG, F. Hoffmann-La Roche LtdA

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Cancer Immunotherapy Market, by Technology
    • 1.4.2 Global Cancer Immunotherapy Market, by Application
    • 1.4.3 Global Cancer Immunotherapy Market, by End User
    • 1.4.4 Global Cancer Immunotherapy Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Global Cancer Immunotherapy Market by Technology

    • 3.1.1 Global Monoclonal Antibodies Cancer Immunotherapy Market by Region
    • 3.1.2 Global Cytokines & Immunomodulators Cancer Immunotherapy Market by Region
    • 3.1.3 Global Other Technology Cancer Immunotherapy Market by Region

Chapter 4. Global Cancer Immunotherapy Market by Application

    • 4.1.1 Global Cancer Immunotherapy Lung Cancer Market by Region
    • 4.1.2 Global Cancer Immunotherapy Breast Cancer Market by Region
    • 4.1.3 Global Cancer Immunotherapy Colorectal Cancer Market by Region
    • 4.1.4 Global Cancer Immunotherapy Melanoma Market by Region
    • 4.1.5 Global Cancer Immunotherapy Prostate Cancer Market by Region
    • 4.1.6 Global Cancer Immunotherapy Head & Neck Cancer Market by Region
    • 4.1.7 Global Other Application Cancer Immunotherapy Market by Region

Chapter 5. Global Cancer Immunotherapy Market by End User

    • 5.1.1 Global Hospitals Cancer Immunotherapy Market by Region
    • 5.1.2 Global Clinics Cancer Immunotherapy Market by Region
    • 5.1.3 Global Other End User Cancer Immunotherapy Market by Region

Chapter 6. Global Cancer Immunotherapy Market by Region

  • 6.1 North America Cancer Immunotherapy Market
    • 6.1.1 North America Cancer Immunotherapy Market by Technology
      • 6.1.1.1 North America Monoclonal Antibodies Cancer Immunotherapy Market by Country
      • 6.1.1.2 North America Cytokines & Immunomodulators Cancer Immunotherapy Market by Country
      • 6.1.1.3 North America Other Technology Cancer Immunotherapy Market by Country
    • 6.1.2 North America Cancer Immunotherapy Market by Application
      • 6.1.2.1 North America Cancer Immunotherapy Lung Cancer Market by Country
      • 6.1.2.2 North America Cancer Immunotherapy Breast Cancer Market by Country
      • 6.1.2.3 North America Cancer Immunotherapy Colorectal Cancer Market by Country
      • 6.1.2.4 North America Cancer Immunotherapy Melanoma Market by Country
      • 6.1.2.5 North America Cancer Immunotherapy Prostate Cancer Market by Country
      • 6.1.2.6 North America Cancer Immunotherapy Head & Neck Cancer Market by Country
      • 6.1.2.7 North America Other Application Cancer Immunotherapy Market by Country
    • 6.1.3 North America Cancer Immunotherapy Market by End User
      • 6.1.3.1 North America Hospitals Cancer Immunotherapy Market by Country
      • 6.1.3.2 North America Clinics Cancer Immunotherapy Market by Country
      • 6.1.3.3 North America Other End User Cancer Immunotherapy Market by Country
    • 6.1.4 North America Cancer Immunotherapy Market by Country
      • 6.1.4.1 US Cancer Immunotherapy Market
        • 6.1.4.1.1 US Cancer Immunotherapy Market by Technology
        • 6.1.4.1.2 US Cancer Immunotherapy Market by Application
        • 6.1.4.1.3 US Cancer Immunotherapy Market by End User
      • 6.1.4.2 Canada Cancer Immunotherapy Market
        • 6.1.4.2.1 Canada Cancer Immunotherapy Market by Technology
        • 6.1.4.2.2 Canada Cancer Immunotherapy Market by Application
        • 6.1.4.2.3 Canada Cancer Immunotherapy Market by End User
      • 6.1.4.3 Mexico Cancer Immunotherapy Market
        • 6.1.4.3.1 Mexico Cancer Immunotherapy Market by Technology
        • 6.1.4.3.2 Mexico Cancer Immunotherapy Market by Application
        • 6.1.4.3.3 Mexico Cancer Immunotherapy Market by End User
      • 6.1.4.4 Rest of North America Cancer Immunotherapy Market
        • 6.1.4.4.1 Rest of North America Cancer Immunotherapy Market by Technology
        • 6.1.4.4.2 Rest of North America Cancer Immunotherapy Market by Application
        • 6.1.4.4.3 Rest of North America Cancer Immunotherapy Market by End User
  • 6.2 Europe Cancer Immunotherapy Market
    • 6.2.1 Europe Cancer Immunotherapy Market by Technology
      • 6.2.1.1 Europe Monoclonal Antibodies Cancer Immunotherapy Market by Country
      • 6.2.1.2 Europe Cytokines & Immunomodulators Cancer Immunotherapy Market by Country
      • 6.2.1.3 Europe Other Technology Cancer Immunotherapy Market by Country
    • 6.2.2 Europe Cancer Immunotherapy Market by Application
      • 6.2.2.1 Europe Cancer Immunotherapy Lung Cancer Market by Country
      • 6.2.2.2 Europe Cancer Immunotherapy Breast Cancer Market by Country
      • 6.2.2.3 Europe Cancer Immunotherapy Colorectal Cancer Market by Country
      • 6.2.2.4 Europe Cancer Immunotherapy Melanoma Market by Country
      • 6.2.2.5 Europe Cancer Immunotherapy Prostate Cancer Market by Country
      • 6.2.2.6 Europe Cancer Immunotherapy Head & Neck Cancer Market by Country
      • 6.2.2.7 Europe Other Application Cancer Immunotherapy Market by Country
    • 6.2.3 Europe Cancer Immunotherapy Market by End User
      • 6.2.3.1 Europe Hospitals Cancer Immunotherapy Market by Country
      • 6.2.3.2 Europe Clinics Cancer Immunotherapy Market by Country
      • 6.2.3.3 Europe Other End User Cancer Immunotherapy Market by Country
    • 6.2.4 Europe Cancer Immunotherapy Market by Country
      • 6.2.4.1 Germany Cancer Immunotherapy Market
        • 6.2.4.1.1 Germany Cancer Immunotherapy Market by Technology
        • 6.2.4.1.2 Germany Cancer Immunotherapy Market by Application
        • 6.2.4.1.3 Germany Cancer Immunotherapy Market by End User
      • 6.2.4.2 UK Cancer Immunotherapy Market
        • 6.2.4.2.1 UK Cancer Immunotherapy Market by Technology
        • 6.2.4.2.2 UK Cancer Immunotherapy Market by Application
        • 6.2.4.2.3 UK Cancer Immunotherapy Market by End User
      • 6.2.4.3 France Cancer Immunotherapy Market
        • 6.2.4.3.1 France Cancer Immunotherapy Market by Technology
        • 6.2.4.3.2 France Cancer Immunotherapy Market by Application
        • 6.2.4.3.3 France Cancer Immunotherapy Market by End User
      • 6.2.4.4 Russia Cancer Immunotherapy Market
        • 6.2.4.4.1 Russia Cancer Immunotherapy Market by Technology
        • 6.2.4.4.2 Russia Cancer Immunotherapy Market by Application
        • 6.2.4.4.3 Russia Cancer Immunotherapy Market by End User
      • 6.2.4.5 Spain Cancer Immunotherapy Market
        • 6.2.4.5.1 Spain Cancer Immunotherapy Market by Technology
        • 6.2.4.5.2 Spain Cancer Immunotherapy Market by Application
        • 6.2.4.5.3 Spain Cancer Immunotherapy Market by End User
      • 6.2.4.6 Italy Cancer Immunotherapy Market
        • 6.2.4.6.1 Italy Cancer Immunotherapy Market by Technology
        • 6.2.4.6.2 Italy Cancer Immunotherapy Market by Application
        • 6.2.4.6.3 Italy Cancer Immunotherapy Market by End User
      • 6.2.4.7 Rest of Europe Cancer Immunotherapy Market
        • 6.2.4.7.1 Rest of Europe Cancer Immunotherapy Market by Technology
        • 6.2.4.7.2 Rest of Europe Cancer Immunotherapy Market by Application
        • 6.2.4.7.3 Rest of Europe Cancer Immunotherapy Market by End User
  • 6.3 Asia Pacific Cancer Immunotherapy Market
    • 6.3.1 Asia Pacific Cancer Immunotherapy Market by Technology
      • 6.3.1.1 Asia Pacific Monoclonal Antibodies Cancer Immunotherapy Market by Country
      • 6.3.1.2 Asia Pacific Cytokines & Immunomodulators Cancer Immunotherapy Market by Country
      • 6.3.1.3 Asia Pacific Other Technology Cancer Immunotherapy Market by Country
    • 6.3.2 Asia Pacific Cancer Immunotherapy Market by Application
      • 6.3.2.1 Asia Pacific Cancer Immunotherapy Lung Cancer Market by Country
      • 6.3.2.2 Asia Pacific Cancer Immunotherapy Breast Cancer Market by Country
      • 6.3.2.3 Asia Pacific Cancer Immunotherapy Colorectal Cancer Market by Country
      • 6.3.2.4 Asia Pacific Cancer Immunotherapy Melanoma Market by Country
      • 6.3.2.5 Asia Pacific Cancer Immunotherapy Prostate Cancer Market by Country
      • 6.3.2.6 Asia Pacific Cancer Immunotherapy Head & Neck Cancer Market by Country
      • 6.3.2.7 Asia Pacific Other Application Cancer Immunotherapy Market by Country
    • 6.3.3 Asia Pacific Cancer Immunotherapy Market by End User
      • 6.3.3.1 Asia Pacific Hospitals Cancer Immunotherapy Market by Country
      • 6.3.3.2 Asia Pacific Clinics Cancer Immunotherapy Market by Country
      • 6.3.3.3 Asia Pacific Other End User Cancer Immunotherapy Market by Country
    • 6.3.4 Asia Pacific Cancer Immunotherapy Market by Country
      • 6.3.4.1 China Cancer Immunotherapy Market
        • 6.3.4.1.1 China Cancer Immunotherapy Market by Technology
        • 6.3.4.1.2 China Cancer Immunotherapy Market by Application
        • 6.3.4.1.3 China Cancer Immunotherapy Market by End User
      • 6.3.4.2 Japan Cancer Immunotherapy Market
        • 6.3.4.2.1 Japan Cancer Immunotherapy Market by Technology
        • 6.3.4.2.2 Japan Cancer Immunotherapy Market by Application
        • 6.3.4.2.3 Japan Cancer Immunotherapy Market by End User
      • 6.3.4.3 India Cancer Immunotherapy Market
        • 6.3.4.3.1 India Cancer Immunotherapy Market by Technology
        • 6.3.4.3.2 India Cancer Immunotherapy Market by Application
        • 6.3.4.3.3 India Cancer Immunotherapy Market by End User
      • 6.3.4.4 South Korea Cancer Immunotherapy Market
        • 6.3.4.4.1 South Korea Cancer Immunotherapy Market by Technology
        • 6.3.4.4.2 South Korea Cancer Immunotherapy Market by Application
        • 6.3.4.4.3 South Korea Cancer Immunotherapy Market by End User
      • 6.3.4.5 Singapore Cancer Immunotherapy Market
        • 6.3.4.5.1 Singapore Cancer Immunotherapy Market by Technology
        • 6.3.4.5.2 Singapore Cancer Immunotherapy Market by Application
        • 6.3.4.5.3 Singapore Cancer Immunotherapy Market by End User
      • 6.3.4.6 Malaysia Cancer Immunotherapy Market
        • 6.3.4.6.1 Malaysia Cancer Immunotherapy Market by Technology
        • 6.3.4.6.2 Malaysia Cancer Immunotherapy Market by Application
        • 6.3.4.6.3 Malaysia Cancer Immunotherapy Market by End User
      • 6.3.4.7 Rest of Asia Pacific Cancer Immunotherapy Market
        • 6.3.4.7.1 Rest of Asia Pacific Cancer Immunotherapy Market by Technology
        • 6.3.4.7.2 Rest of Asia Pacific Cancer Immunotherapy Market by Application
        • 6.3.4.7.3 Rest of Asia Pacific Cancer Immunotherapy Market by End User
  • 6.4 LAMEA Cancer Immunotherapy Market
    • 6.4.1 LAMEA Cancer Immunotherapy Market by Technology
      • 6.4.1.1 LAMEA Monoclonal Antibodies Cancer Immunotherapy Market by Country
      • 6.4.1.2 LAMEA Cytokines & Immunomodulators Cancer Immunotherapy Market by Country
      • 6.4.1.3 LAMEA Other Technology Cancer Immunotherapy Market by Country
    • 6.4.2 LAMEA Cancer Immunotherapy Market by Application
      • 6.4.2.1 LAMEA Cancer Immunotherapy Lung Cancer Market by Country
      • 6.4.2.2 LAMEA Cancer Immunotherapy Breast Cancer Market by Country
      • 6.4.2.3 LAMEA Cancer Immunotherapy Colorectal Cancer Market by Country
      • 6.4.2.4 LAMEA Cancer Immunotherapy Melanoma Market by Country
      • 6.4.2.5 LAMEA Cancer Immunotherapy Prostate Cancer Market by Country
      • 6.4.2.6 LAMEA Cancer Immunotherapy Head & Neck Cancer Market by Country
      • 6.4.2.7 LAMEA Other Application Cancer Immunotherapy Market by Country
    • 6.4.3 LAMEA Cancer Immunotherapy Market by End User
      • 6.4.3.1 LAMEA Hospitals Cancer Immunotherapy Market by Country
      • 6.4.3.2 LAMEA Clinics Cancer Immunotherapy Market by Country
      • 6.4.3.3 LAMEA Other End User Cancer Immunotherapy Market by Country
    • 6.4.4 LAMEA Cancer Immunotherapy Market by Country
      • 6.4.4.1 Brazil Cancer Immunotherapy Market
        • 6.4.4.1.1 Brazil Cancer Immunotherapy Market by Technology
        • 6.4.4.1.2 Brazil Cancer Immunotherapy Market by Application
        • 6.4.4.1.3 Brazil Cancer Immunotherapy Market by End User
      • 6.4.4.2 Argentina Cancer Immunotherapy Market
        • 6.4.4.2.1 Argentina Cancer Immunotherapy Market by Technology
        • 6.4.4.2.2 Argentina Cancer Immunotherapy Market by Application
        • 6.4.4.2.3 Argentina Cancer Immunotherapy Market by End User
      • 6.4.4.3 UAE Cancer Immunotherapy Market
        • 6.4.4.3.1 UAE Cancer Immunotherapy Market by Technology
        • 6.4.4.3.2 UAE Cancer Immunotherapy Market by Application
        • 6.4.4.3.3 UAE Cancer Immunotherapy Market by End User
      • 6.4.4.4 Saudi Arabia Cancer Immunotherapy Market
        • 6.4.4.4.1 Saudi Arabia Cancer Immunotherapy Market by Technology
        • 6.4.4.4.2 Saudi Arabia Cancer Immunotherapy Market by Application
        • 6.4.4.4.3 Saudi Arabia Cancer Immunotherapy Market by End User
      • 6.4.4.5 South Africa Cancer Immunotherapy Market
        • 6.4.4.5.1 South Africa Cancer Immunotherapy Market by Technology
        • 6.4.4.5.2 South Africa Cancer Immunotherapy Market by Application
        • 6.4.4.5.3 South Africa Cancer Immunotherapy Market by End User
      • 6.4.4.6 Nigeria Cancer Immunotherapy Market
        • 6.4.4.6.1 Nigeria Cancer Immunotherapy Market by Technology
        • 6.4.4.6.2 Nigeria Cancer Immunotherapy Market by Application
        • 6.4.4.6.3 Nigeria Cancer Immunotherapy Market by End User
      • 6.4.4.7 Rest of LAMEA Cancer Immunotherapy Market
        • 6.4.4.7.1 Rest of LAMEA Cancer Immunotherapy Market by Technology
        • 6.4.4.7.2 Rest of LAMEA Cancer Immunotherapy Market by Application
        • 6.4.4.7.3 Rest of LAMEA Cancer Immunotherapy Market by End User

Chapter 7. Company Profiles

  • 7.1 Amgen Inc.
    • 7.1.1 Company Overview
    • 7.1.2 Financial Analysis
    • 7.1.3 Segmental & Regional Analysis
    • 7.1.4 Research and Development Expense
  • 7.2 Merck & Company, Inc.
    • 7.2.1 Company Overview
    • 7.2.2 Financial Analysis
    • 7.2.3 Regional and Segmental Analysis
    • 7.2.4 Research & Development
  • 7.3 Pfizer Inc.
    • 7.3.1 Company Overview
    • 7.3.2 Financial Analysis
    • 7.3.3 Segmental &Regional Analysis
    • 7.3.4 Revenue analysis by Region
    • 7.3.5 Research and Development
  • 7.4 Immunomedics Inc.
    • 7.4.1 Company Overview
    • 7.4.2 Financial Analysis
    • 7.4.3 Revenue Analysis by Region
    • 7.4.4 Research and Development
  • 7.5 Astrazeneca Plc.
    • 7.5.1 Company Overview
    • 7.5.2 Financial Analysis
    • 7.5.3 Segmental analysis
    • 7.5.4 Research & Development
  • 7.6 F. Hoffmann-La Roche Ltd.
    • 7.6.1 Company Overview
    • 7.6.2 Financial Analysis
    • 7.6.3 Revenue & Segment analysis
    • 7.6.4 Research and Development
  • 7.7 Eli Lilly and Company
    • 7.7.1 Company Overview
    • 7.7.2 Financial Analysis
    • 7.7.3 Segmental and Regional Analysis
    • 7.7.4 Research & Development Expense
  • 7.8 Novartis AG
    • 7.8.1 Company Overview
    • 7.8.2 Financial Analysis
    • 7.8.3 Segmental and Regional Analysis
    • 7.8.4 Research & Development Expense
  • 7.9 Bristol-Myers Squibb Company
    • 7.9.1 Company Overview
  • 7.1 Bayer AG
    • 7.10.1 Company Overview
    • 7.10.2 Financial Analysis
    • 7.10.3 Segmental and Regional Analysis
    • 7.10.4 Research & Development Expense
Back to Top